Moreover, the transcriptional activity of SOX2 and/or OCT4, measured using the SORE6 reporter, is a bona fide CSC marker in sarcoma and constitutes an excellent approach for testing the effectiveness of anti-tumor treatments to target CSCs. Here, SOX2 is linked to sarcoma.